CEO Roger Kahn and director Michael Ketslakh have accumulated more than 78,000 shares over the past two months, with buying accelerating at prices below $1. Short interest has tripled in 30 days to 0.11% of float. Stock closed at $1, up 7% Friday and 18% in the past month.
BLIN closed at $1.00 on April 24, up 7% on the day. The stock gained 12.6% over the past week and 17.6% over the past month. The application software provider trades without a reported market cap.
Short interest rose 11% on April 23 to 13,020 shares. That represents 0.11% of the free float. Over the past month, short interest has surged 230%, tripling from early-March levels. The March 23 reading of 4,116 shares marked the recent low. Short shares jumped above 12,000 by mid-April and have held there since.
Cost to borrow sits at 3.69%, flat over the past week and down 3.7% over the past month. The 30-day high was 4.43% on March 31. Utilisation reached 2.0% on April 23, up from 1.58% a week earlier. The 52-week high of 36.01% was set in 2025.
WestPark Capital's Casey Ryan maintains a Buy rating with a $4.62 price target, unchanged since December 2025. Ladenburg Thalmann's Jon Hickman initiated coverage in September 2022 with a Buy and a $4.50 target. The mean target of $4.06 is four times the current price. Analyst coverage has been inactive since early 2025, with the latest data 424 days old.
WestPark upgraded BLIN to Buy from Hold in February 2025, announcing the $4.62 target. The firm initiated coverage with a Hold in July 2024.
The stock trades at a P/E of 9.74 as of September 2023, down 2.91 points over the past month. EV/EBITDA sits at 6.01 as of July 2024, up 0.91 points in the past month. Earnings yield calculated at 10.26% in September 2023 has risen 2.36 percentage points over 30 days.
BLIN ranks in the 88th percentile on ORTEX's short score and the 82nd percentile for days to cover. Utilisation ranks 68th percentile. EPS surprise sits at the 69th percentile. Sector score is 30th percentile. Dividend score is 32nd percentile.
Roger Kahn, categorized as an institutional holder, increased his stake by 364,301 shares through March 10, bringing his position to 1.77 million shares, or 14.08% of the company. Bard Associates trimmed 229,454 shares by year-end 2025, leaving 1.16 million shares (9.2%). Michael Ketslakh added 21,353 shares through March 3, holding 493,842 (3.92%).
Citadel added 86,769 shares by year-end, reaching 117,838. Lido Advisors initiated a 57,620-share position. DRW Holdings initiated with 54,438 shares. Renaissance Technologies cut 26,100 shares, holding 146,129.
Insiders purchased 101,174 shares over the past 90 days, worth $82,437. Net activity is entirely positive.
CEO Roger Kahn bought 64,301 shares across four transactions between February 17 and March 10. The largest was 35,301 shares at $0.75 on February 17, worth $26,476. He added 14,000 shares at $0.82 on February 18 and 10,000 at $0.93 on March 10. His stake now stands at 14.08% of the company.
Director Michael Ketslakh bought 21,353 shares across six transactions from February 18 to March 3. He accumulated 10,647 shares at $0.85 on February 25, worth $9,050. Smaller buys ranged from 1,353 to 4,472 shares. His position is 3.92% of shares.
Independent Chairman Joni Kahn sold 7,252 shares at $0.82 on January 30, netting $5,947. Her stake fell to 0.24%.
Earnings are scheduled for May 14 at 8:00 PM UTC. The company reported four times in February 2026, with announcements clustered around the February 11–12 period.
See the live data behind this article on ORTEX.
Open BLIN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
